Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases
- PMID: 28506849
- DOI: 10.1016/j.jaci.2017.04.029
Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases
Keywords: Drug development; biomarker; clinical trials; pharmacodynamics; trial design.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
